LISA-TRACKER anti-Certolizumab
Product Description
LISA-TRACKER anti-Certolizumab is an enzyme linked immunoassay for the quantitative determination of human anti-Certolizumab pegol antibodies in human serum samples.
- Comprehensive menu in inflammatory diseases and oncology
- Validated on principle drug and biosimilars
- Ready to use reagents
- Standardised protocols from sample collection to result interpretation
- Automation ready – protocols available on several open platform ELISA systems
-
- Choy EHS et al. Efficacy of a novel PEGylated humanized anti-TNF (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose escalating trial. Rheumatology 2002;41:1133-1137.
- Desroches M et al. Treatment failure with antagonists of TNF-α: mechanisms and implications for the care of patients. Eur. Cytokine Netw., Vol. 21 n° 4, December 2010, 226-31.
- Edrees AF et al. Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. Clin Exp Rheumatol. 2005 Jul-Aug;23(4):469-74.
- Koren E et al. Recommendation on risk-based strategies for detection and characterization of antibodies against biotechnology products. Journal of Immunological Methods, 333 (2008) 1-9.
- Ram Raj Singh, & al. TNFα blockade in human diseases: mechanisms and future. Clin.Immunol., 2008 February; 126(2):121-136.
- Vetterlein O et al. No antibodies to PEG detected in patients treated with certolizumab pegol. Ann Rheum Dis 2008;67(Suppl II):236.
- Product Code: LTC-003-48
- Number of Tests: 48
- Sample Type: Serum or plasma
- Sample Volume: 100 μL (following predilution)
- Assay Range: 5 – 160 AU/mL
- Add to Enquiry Basket
Interested? Enquire now.
Add to Enquiry Basket
Related Products
| Assays | Certification | Platform | Clinical Area | Portfolio | RUO/IVD |
|---|---|---|---|---|---|
| LISA-TRACKER Certolizumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Certolizumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Infliximab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Adalimumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Etanercept | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Secukinumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Golimumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Ustekinumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD |